التفاصيل البيبلوغرافية
| العنوان: |
Short‐term effects of sacubitril/valsartan therapy on myocardial oxygen consumption and energetic efficiency of cardiac work in heart failure with reduced ejection fraction: A randomized controlled study. |
| المؤلفون: |
Nesterov, Sergey V., Räty, Johanna, Nammas, Wail, Maaniitty, Teemu, Galloo, Xavier, Stassen, Jan, Laurila, Sanna, Vasankari, Tuija, Huusko, Jenni, Bax, Jeroen J., Saraste, Antti, Knuuti, Juhani |
| المصدر: |
European Journal of Heart Failure; Jan2024, Vol. 26 Issue 1, p117-126, 10p |
| مصطلحات موضوعية: |
OXYGEN consumption, HEART failure, VENTRICULAR ejection fraction, POSITRON emission tomography, ENTRESTO |
| مستخلص: |
Aims: We sought to evaluate the mechanism of angiotensin receptor–neprilysin inhibitor (ARNI) sacubitril/valsartan therapy and compare it with a valsartan‐only control group in patients with heart failure with reduced ejection fraction (HFrEF). Methods and results: The study was a phase IV, prospective, randomized, double‐blind, parallel‐group study in patients with New York Heart Association class II–III heart failure and left ventricular ejection fraction (LVEF) ≤35%. During a 6‐week run‐in period, all patients received valsartan therapy, which was up‐titrated to the highest tolerated dose level (80 mg bid or 160 mg bid) and then randomized to either valsartan or sacubitril/valsartan. Myocardial oxygen consumption, energetic efficiency of cardiac work, cardiac and systemic haemodynamics were quantified using echocardiography and 11C‐acetate positron emission tomography before and after 6 weeks of therapy (on stable dose) in 55 patients (ARNI group: n = 27, mean age 63 ± 10 years, LVEF 29.2 ± 10.4%; and valsartan‐only control group: n = 28, mean age 64 ± 8 years, LVEF 29.0 ± 7.3%; all p = NS). The energetic efficiency of cardiac work remained unchanged in both treatment arms. However, both diastolic (−4.5 mmHg; p = 0.026) and systolic blood pressure (−9.8 mmHg; p = 0.0007), myocardial perfusion (−0.054 ml/g/min; p = 0.045), and left ventricular mechanical work (−296; p = 0.038) decreased significantly in the ARNI group compared to the control group. Although myocardial oxygen consumption decreased in the ARNI group (−5.4%) compared with the run‐in period and remained unchanged in the control group (+0.5%), the between‐treatment group difference was not significant (p = 0.088). Conclusions: We found no differences in the energetic efficiency of cardiac work between ARNI and valsartan‐only groups in HFrEF patients. However, ARNI appears to have haemodynamic and cardiac mechanical effects over valsartan in heart failure patients. [ABSTRACT FROM AUTHOR] |
|
Copyright of European Journal of Heart Failure is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder